Advertisement

Search Results

Advertisement



Your search for The ASCO Post Staff,The ASCO Post Staff matches 6512 pages

Showing 301 - 350


skin cancer

Roswell Park Announces Center’s First Physician-in-Chief

Candace S. Johnson, PhD, President and Chief Executive Officer of Roswell Park Comprehensive Cancer Center, recently announced the appointment of Michael Wong, MD, PhD, FRPC, as the cancer center’s first Physician-in-Chief. Dr. Wong is a medical oncologist and skin cancer expert, who joined...

bladder cancer

Novel Oncolytic Immunotherapy Yields Durable Responses in High-Risk Bladder Cancer

A novel immunotherapy may offer a new option for patients with bladder cancer who no longer respond to bacillus Calmette-Guérin (BCG), according to a study presented on December 5 at the 2024 Society of Urologic Oncology Annual Meeting in Dallas. The therapy, cretostimogene grenadenorepvec, is an...

issues in oncology

Understanding How Stigma and Incorrect Physician Assumptions About LGBTQ+ Patients’ Needs Contribute to Medical Mistrust

Over the past decade, ASCO has focused its resources on advancing health equity for sexual and gender minority (SGM) individuals with cancer. In 2017, the Society published a position statement “Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations,” which...

issues in oncology

Impact of Prevention and Screening on Mortality From Five Common Cancers

Improvements in cancer prevention and screening have averted more deaths from five cancer types combined over the past 45 years than treatment advances, according to a modeling study led by researchers at the National Institutes of Health (NIH). The study, published by Goddard et al in JAMA...

breast cancer
immunotherapy
genomics/genetics

Novel Immunotherapy May Offer Benefit in Early Clinical Trial for Breast Cancer

A novel cell-based immunotherapy may enhance treatment responses and reduce the need for conventional chemotherapy and its associated toxicities in patients with breast cancer, according to a recent study published by Han et al in JAMA Oncology. Study Methods and Results In the phase I clinical...

breast cancer
issues in oncology

Self-Pay, AI-Based Program May Help Boost Mammogram Findings

A self-pay, artificial intelligence (AI)-enhanced breast cancer screening program could help improve breast cancer detection rates, according to new findings presented by Sorensen et al at the Radiological Society of North America (RSNA) 2024 Annual Meeting (Abstract R5B-SPBR-4). Background Despite ...

hepatobiliary cancer

Accelerated Approval Granted to Zanidatamab-hrii for HER2-Positive Biliary Tract Cancer

The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test. The FDA also...

leukemia

Oral Liquid Imatinib Approved by the FDA in Leukemia

The U.S. Food and Drug Administration (FDA) recently has approved an oral solution of the tyrosine kinase inhibitor, imatinib mesylate, called Imkeldi, to treat certain types of leukemia and other cancers. The new solution is an advanced liquid formulation of imatinib designed to provide dosing...

head and neck cancer

Cetuximab vs Durvalumab in Treatment of Head and Neck Cancers

Durvalumab, an immune checkpoint inhibitor, has shown activity in treating a wide range of cancers and has been proposed as a potentially safer and more effective option than cetuximab, according to Loren K. Mell, MD, Professor and Vice Chair of Clinical and Translational Research at University of ...

FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer

On December 4, 2024, the U.S. Food and Drug Administration approved durvalumab (Imfinzi) for adults with limited-stage small cell lung cancer (SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Efficacy was evaluated in ADRIATIC...

multiple myeloma

IMF Welcomes Newly Elected Board of Directors Members

The International Myeloma Foundation (IMF) welcomes four of its newest members to the IMF Board of Directors: Director of Strategic Growth at Raanes & Oliver Capital Advisors, Kent Oliver; Managing Partner of Global Commercialization Strategy and Solutions at ZS Associates, Maria Whitman;...

breast cancer
immunotherapy

Updated Findings in Preventive Breast Cancer Vaccine Study

Researchers from Cleveland Clinic recently presented updated findings from a novel study of a vaccine aimed at preventing triple-negative breast cancer. The findings were presented at the Society for Immunotherapy of Cancer Annual Meeting.1 According to researchers, including principal...

hematologic malignancies

ASH Announces Recipients of 2024 ASH Advocacy Awards

The American Society of Hematology (ASH) honored Rep. Michael Burgess, MD (R-TX) and Centers for Disease Control and Prevention (CDC) health scientist Mary Hulihan, DrPH, for their leadership on issues of importance to hematology research and practice at the 2024 ASH Annual Meeting &...

lung cancer
pancreatic cancer

FDA Grants Approval to New Bispecific Antibody for NSCLC and Pancreatic Adenocarcinoma

On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to the HER2 × HER3 bispecific antibody zenocutuzumab-zbco (Bizengri) for adults with the following types of lung and pancreatic cancers: advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC)...

colorectal cancer
bladder cancer
prostate cancer
issues in oncology

Potential Cancer Vaccine Target Uncovered in E coli Bacteria

Targeting certain bacterial strains linked to cancer with treatments or vaccines may help to reduce the risk of colorectal cancer, urothelial carcinoma, and prostate cancer, according to a novel study published by Mäklin et al in The Lancet Microbiome. Background The bacterium Escherichia coli is...

solid tumors
health-care policy
legislation

Prior Authorization Delays May Lead to Severe Consequences for Patients With Cancer

A recent nationwide survey has confirmed that prior authorization may cause treatment delays, abandoned treatments, hospitalizations, and deaths among patients with cancer, according to an executive summary published by the American Society for Radiation Oncology (ASTRO). The findings may reinforce ...

cns cancers

Temozolomide Plus Radiotherapy for Low-Grade Gliomas

Based on the phase III E3F05 trial, conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), the combination of radiation therapy and temozolomide appeared to be more effective than radiotherapy alone in the treatment of low-grade gliomas. The trial followed 172 patients for more than 10...

head and neck cancer
immunotherapy

Novel Combination Studied in HPV16-Positive Relapsed or Metastatic Head and Neck Squamous Cell Carcinoma

  Alan Ho, MD, PhD, recently presented updated results from a phase II trial evaluating the combination of an HPV16-targeted investigational immunotherapeutic agent eseba-vec (previously known as HB-200) and the PD-1 inhibitor pembrolizumab as first-line therapy for human papillomavirus type 16...

immunotherapy

Study Highlights From MD Anderson Researchers

Here are some highlights of clinical trials presented at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center. They include breakthroughs in cancer care, updates in clinical research, and efforts in cancer...

lung cancer

Study Evaluating Lung Cancer Screening Program Receives Margulis Award for Scientific Excellence

The 2024 Alexander R. Margulis Award for Scientific Excellence honored the authors of a 20-year follow-up study on the International Early Lung Cancer Action Program (I-ELCAP). The Margulis Award was presented recently during the 2024 Radiological Society of North America (RSNA) Scientific Assembly ...

breast cancer

Impact of Menopausal Status on Long-Term Benefit From Antihormonal Treatment in Women With Breast Cancer

New research has shown that postmenopausal women with low-risk tumors have a long-term benefit for at least 20 years, whereas the benefit was more short-term for younger women with similar tumor characteristics who had not yet gone through menopause. The results were reported in the Journal of the ...

solid tumors
issues in oncology
lung cancer

Regional, Racial, Economic Disparities in Air Pollution–Related Cancer Risk May Be Improving but Still Persist

Investigators report they have uncovered patterns in the risk of cancer associated with lifetime exposure to air pollution and how this risk may have changed over time, in a recent study published by Hurbain et al in Environmental Science & Technology. The findings could build on the scientific ...

immunotherapy
issues in oncology
solid tumors
cns cancers
skin cancer
gynecologic cancers

Challenges, Potential of Mesenchymal Stem Cells in Cancer Immunotherapy

Investigators have assessed the potential role of mesenchymal stem cells in cancer treatment in a new review published by Minev et al in Oncotarget. Study Overview and Implications The investigators found that mesenchymal stem cells can naturally target tumors and deliver therapeutic agents...

leukemia

Obecabtagene Autoleucel in Adults With B-Cell ALL

A second-generation chimeric antigen receptor (CAR) T-cell therapy may offer a new option for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), an aggressive blood cancer with few treatment options. Results from the phase Ib/II FELIX trial, published by Roddie et al in ...

breast cancer

Komal Jhaveri, MD, FACP, on Antibody-Drug Conjugates in Breast Cancer

Komal Jhaveri, MD, FACP, is an Associate Professor of Clinical Medicine at Weill Cornell Medical College and a Breast Medical Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center in New York. In this video from The ASCO Post Newreels, Dr. Jhaveri shares a...

gastrointestinal cancer
colorectal cancer
gastroesophageal cancer
pancreatic cancer

Poor Diets May Increase Risk of Gastrointestinal Cancer

New research may expand on existing evidence that a healthy diet may protect against gastrointestinal cancers and improve disease outcomes, according to a recent study published by Abebe et al in the European Journal of Nutrition. Background Gastrointestinal cancers including esophageal, gastric,...

lung cancer
cardio-oncology
issues in oncology

Lung Cancer CT Screening May Help to Detect Coronary Artery Disease

Lung cancer screening with low-dose chest computed tomography (CT) may be capable of identifying coronary artery calcium in patients without cardiac symptoms, according to a recent study published by Caires et al in the Canadian Medical Association Journal. Background Lung cancer is currently one...

lung cancer
issues in oncology

Pharmacokinetic Comparison of Aumolertinib, Osimertinib, Gefitinib, and Their Major Metabolites in NSCLC

Researchers may have established an accurate ultraperformance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for comparing the pharmacokinetic properties of three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and their major metabolites in mouse...

immunotherapy
issues in oncology

Study May Illuminate Cause of Common Checkpoint Inhibitor Adverse Effect

Researchers may have uncovered the factors contributing to an increased susceptibility to common infections among patients with cancer receiving checkpoint inhibitors, according to a recent study published by Ogishi et al in Immunity. The findings may provide new insights into immune responses and...

colorectal cancer
issues in oncology

At-Home Testing Kits, Coordinated Outreach May Improve Colorectal Cancer Screening Rates

Researchers have demonstrated that a targeted intervention may increase screening rates in patients who do not adhere to current colorectal cancer screening recommendations, according to a recent study published by Reuland et al in JAMA Network Open. Background Colorectal cancer screening is often...

supportive care
solid tumors
issues in oncology

Peer Support Intervention May Help Improve Psychological Outcomes Among Patients With Cancer in Low-Resource Settings

Researchers have found that the cancer peer support program Stronger Together may provide critical social support to patients with cancer, particularly in low-resource settings in low- and middle-income countries, according to a recent study published by Le et al in JCO Global Oncology. Background...

leukemia
myelodysplastic syndromes
gastroesophageal cancer
solid tumors
hematologic malignancies

FDA Approves Oral Liquid Imatinib to Treat Patients With Leukemia and Other Cancer Types

The U.S. Food and Drug Administration (FDA) announced the approval of imatinib (Imkeldi) oral solution, the first oral liquid formulation of the drug to treat certain types of leukemias and other cancers. Background In 2024, an estimated 9,280 patients will be diagnosed with chronic myeloid...

cns cancers
issues in oncology

Adding Temozolomide to Radiation Therapy May Improve Survival in Adults With Low-Grade Gliomas

Both radiation and temozolomide may have meaningful single-modality antitumor activity against slow-growing, low-grade gliomas, according to recent findings presented by Schiff et al at the 2024 Society for Neuro-Oncology Annual Meeting (Abstract LTBK-07) and simultaneously published in...

breast cancer
leukemia
hepatobiliary cancer
solid tumors
hematologic malignancies

Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer

The studies summarized below were reported online over the past month in The ASCO Post, generating a high number of visitors.  For comprehensive reviews of these studies and more, visit ASCOPost.com. Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer In the phase...

breast cancer
gynecologic cancers
prostate cancer
pancreatic cancer

NCCN Guidelines Expanded to Meet Growing Understanding of Hereditary Risk

The National Comprehensive Cancer Network (NCCN) introduced expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to account for the advanced understanding of hereditary cancer risk in breast, ovarian, pancreatic, and prostate cancers.1 “The recently updated NCCN Guidelines for ...

hepatobiliary cancer

Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma

The National Medical Products Administration (NMPA) of China has accepted a supplemental new drug application (sNDA) for penpulimab, a differentiated PD-1 monoclonal antibody, in combination with the multikinase inhibitor anlotinib for the first-line treatment of advanced hepatocellular carcinoma...

cns cancers

Global Adaptive Platform Trial for Glioblastoma to Evaluate Novel ATM Kinase Inhibitor

The Global Coalition for Adaptive Research (GCAR) announced an agreement to evaluate AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor developed by AstraZeneca, in GCAR’s Glioblastoma Adaptive Global Innovative Learning Environment trial (GBM AGILE; ClinicalTrials.gov identifier...

breast cancer
issues in oncology
genomics/genetics

Healthy Women May Have Aneuploid Epithelial Cells Resembling Breast Cancer

Researchers have found that in healthy women, some breast cells that otherwise appear normal may contain chromosome abnormalities typically associated with invasive breast cancer, according to a recent study published by Lin et al in Nature. The findings challenged conventional thinking on the...

hematologic malignancies
issues in oncology

Impact of ASH Minority Recruitment Initiative on Retaining, Engaging Underrepresented Hematologists

Participants of the American Society of Hematology (ASH) Minority Recruitment Initiative had lower attrition rates in graduate and medical programs, were more likely to pursue a career in hematology, and had high levels of engagement at ASH beyond their participation in the program, according to a ...

hepatobiliary cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test. The FDA also approved ...

cns cancers
issues in oncology

Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis, Monitoring, and Treatment

An international, multidisciplinary team of neuro-oncology researchers and physicians has developed new clinical practice recommendations for the use of artificial intelligence (AI) methods to more accurately diagnose, monitor, and treat patients with brain cancer. The guidelines were described in...

breast cancer
issues in oncology

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

Investigators have found that firefighters may face occupational exposures to multiple chemicals that could increase their risk of developing breast cancer, according to a recent study published by Cardona et al in Toxics. Background Prior research has revealed that firefighters have significantly...

breast cancer

Vered Stearns, MD, on Shifting Patient Outcomes: Updates in Triple-Negative Breast Cancer

Vered Stearns, MD, is the Director for Translational Breast Cancer Research in the Department of Hematology and Medical Oncology at Sandra and Edward Meyer Cancer Center and Weill Cornell Medical School. Dr. Stearns talks about updates in the management of patients with triple-negative breast...

hematologic malignancies

ASH to Present 2024 Honorific Awards at Annual Meeting

The American Society of Hematology (ASH) will recognize exemplary hematologists who have made significant contributions to the field with several honorific awards at the 2024 ASH Annual Meeting and Exposition, being held December 7–10 in San Diego. “ASH is honored to recognize these outstanding...

issues in oncology

Project Facilitate: 5 Years of Progress, Outreach, and Service

OCE Insights is developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Lieutenant Commander Mitchell Chan, PharmD, BCPS, Team Lead and Clinical Analyst, Lieutenant Cameron Wilson, PharmD, BCPS, BCCCP, ...

solid tumors
issues in oncology
thyroid cancer
skin cancer

Suicide-Related Mortality in Male AYA Cancer Survivors

Investigators have found that among all cancer survivors, male adolescents and young adults (AYAs) may have the highest rate of suicide-related mortality, according to a recent study published by Matsuo et al in JAMA Network Open. Cancer is becoming more common among young patients, and cancer...

global cancer care
gynecologic cancers

International Cancer Organizations Present Collaborative Work During Oncology Event in China

The National Comprehensive Cancer Network (NCCN) took part in the 2024 International Congress of the Asian Oncology Society and the 2024 Chinese Congress on Holistic Integrative Oncology, which highlighted international collaborations to improve cancer therapy and outcomes across China and Asia....

hematologic malignancies
solid tumors
immunotherapy
genomics/genetics
issues in oncology

New Technique May Allow for Visualization of CAR T Cells Postinjection

The University of Cincinnati Cancer Center announced the launch of a new study funded by a $2.3 million National Cancer Institute (NCI) grant to develop a novel technique to visualize where genetically modified immune cells go after being administered in patients with cancer. Background During...

breast cancer
solid tumors
genomics/genetics
issues in oncology

AI Tool May Detect Cancer Gene Signatures in Biopsy Images

Researchers have developed an artificial intelligence (AI)-powered computational program that may be capable of predicting the activity of thousands of genes within tumor cells based on standard microscopy images of a biopsy, according to a recent study published by Pizurica et al in Nature...

prostate cancer

Study Identifies New Approach to Overcome Docetaxel Resistance in Patients With Advanced Prostate Cancer

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other targets to treat prostate cancer are still necessary to prolong life and slow the progression of...

Advertisement

Advertisement




Advertisement